Serinus Biosciences
Combinations therapy by rational design
Serinus Biosciences is tackling one of the toughest problems in cancer treatment: creating combination therapies to override treatment resistance. We leverage cutting edge technology to design a fully explainable AI platform primed with decades of system biology knowledge. Uniquely powered for biological inference, our AI engine uncovers how cancer cells evolve treatment resistance and identifies molecules to overcome resistance escape routes. We design combinations that are safer, more effective, and can get to patients quickly. Founded by MIT PhDs and supported by a scientific advisory board of top academics from the Broad Institute, Dana-Farber, and UCSD, Serinus is powered by Y Combinator and other top investors to revolutionize precision medicine.
- Website
- serinus.bio
- City
- New York City
- Country
- United States
- YC batch
- Summer 2022
- Team
- 6 people
- Stage
- Early stage
- AI-native
- Yes
More Health & bio in New York City
Ro$5bn
Health technology. Valued at $5bn (March 2021).
Noom$3.7bn
Healthcare. Valued at $3.7bn (May 2021).
Headway$2.3bn
Healthcare. Valued at $2.3bn (July 2024).
Sword Health$2bn
Health. Valued at $2bn (November 2021).
H1
Connecting stakeholders across the healthcare ecosystem.
Opentrons
We make robots for biologists.
Claim this profile
Free and instant: prove you run serinus.bio and edit the profile yourself.
- Your logo, office address and founder photos
- The ✓ Verified mark next to Serinus Biosciences across the site
- Open roles listed on the Hiring board
- A followed link back to your website
A rank card with Serinus Biosciences's standing on Labspie, or a simple badge. Both link to this profile and update themselves.
